{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:15Z","timestamp":1792167495420,"version":"4.4.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["19lk0201104h0001"],"award-info":[{"award-number":["19lk0201104h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder of unknown etiology with systemic symptoms that include fever, night sweats, weight loss, and fatigue. Although tocilizumab (TCZ), which is a recombinant, humanized, anti-human interleukin 6 receptor monoclonal antibody, has been recommended to treat patients with iMCD, 40% of patients with iMCD do not achieve complete remission with TCZ treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design:<\/jats:title>\n            <jats:p>In this phase II, investigator-initiated, multicenter, double-blind, randomized, parallel-group trial, the efficacy and safety of sirolimus will be compared with placebo in patients with TCZ-resistant iMCD. The study will be conducted in 8 centers in Japan. Participants (n\u200a=\u200a20) will be randomly assigned to receive 2\u200amg of oral sirolimus (n\u200a=\u200a10) or placebo (n\u200a=\u200a10) once daily for 16 weeks. The primary endpoint is a decrease in CHAP score by \u22651 from baseline at 16 weeks. Secondary endpoints include levels of hemoglobin, albumin, and C-reactive protein; change in CHAP score; SF-36 Health Survey Questionnaire; physician global assessment (100\u200amm visual analog scale); patient global assessment (100\u200amm visual analog scale) at 2, 4, 8, 12, and 16 weeks; change in lymphadenopathy at 16 weeks; and pharmacodynamic assessment, including the measurement of whole blood sirolimus level.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>This clinical trial will provide evidence of efficacy and safety of sirolimus as a potential new therapeutic agent for patients with TCZ-resistant iMCD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial Registration:<\/jats:title>\n            <jats:p>This study was registered with the Japan Registry of Clinical Trials as jRCT2071190029 on October 8, 2019.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020710","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:06:14Z","timestamp":1595372774000},"page":"e20710","source":"Crossref","is-referenced-by-count":11,"title":["Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease"],"prefix":"10.1097","volume":"99","author":[{"given":"Tomohiro","family":"Koga","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences"},{"name":"Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Hagimori","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Takemori","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi","family":"Sumiyoshi","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences"},{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences"},{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizu","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00000478-198304000-00001","article-title":"A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients","volume":"7","author":"Frizzera","year":"1983","journal-title":"Am J Surg Pathol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/02841860410002752","article-title":"Fifty years of multicentric Castleman's disease","volume":"43","author":"Waterston","year":"2004","journal-title":"Acta Oncol"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-128-8-199804150-00010","article-title":"The clinical behavior of localized and multicentric Castleman disease","volume":"128","author":"Herrada","year":"1998","journal-title":"Ann Intern Med"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1634\/theoncologist.2011-0075","article-title":"Castleman's disease: systematic analysis of 416 patients from the literature","volume":"16","author":"Talat","year":"2011","journal-title":"Oncologist"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3960\/jslrt.53.69","article-title":"Clinical features and treatment of multicentric Castleman's disease: a retrospective study of 21 Japanese patients at a single institute","volume":"53","author":"Kawabata","year":"2013","journal-title":"J Clin Exp Hematop"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V95.4.1406.004k26_1406_1412","article-title":"HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma","volume":"95","author":"Dupin","year":"2000","journal-title":"Blood"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/PAP.0b013e3181a9d4d3","article-title":"Castleman disease: an update on classification and the spectrum of associated lesions","volume":"16","author":"Cronin","year":"2009","journal-title":"Adv Anat Pathol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2013-12-545087","article-title":"HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy","volume":"123","author":"Fajgenbaum","year":"2014","journal-title":"Blood"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14397595.2017.1366093","article-title":"Tentative diagnostic criteria and disease severity classification for Castleman disease: a report of the research group on Castleman disease in Japan","volume":"28","author":"Fujimoto","year":"2018","journal-title":"Mod Rheumatol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a \u2019chemokine storm\u2019 in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ajh.24242","article-title":"Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease","volume":"91","author":"Iwaki","year":"2016","journal-title":"Am J Hematol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","article-title":"Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression","volume":"23","author":"Fingar","year":"2004","journal-title":"Oncogene"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"130","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical","year":"2013","journal-title":"JAMA"},{"key":"R19-20230915","first-page":"953","article-title":"Biased coin design with imbalance tolerance. Communications in statistics","volume":"15","author":"Chen","year":"1999","journal-title":"Stoch Models"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1513\/AnnalsATS.201605-335OC","article-title":"Efficacy and safety of long-term sirolimus therapy for Asian patients with lymphangioleiomyomatosis","volume":"13","author":"Takada","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:03:02Z","timestamp":1694826182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020710"}},"subtitle":["Study protocol for clinical trial"],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":22,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020710","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]}}}